• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina

    6/17/24 8:32:43 AM ET
    $YTEN
    Get the next $YTEN alert in real time by email

    WOBURN, Mass. and HARPENDEN, United Kingdom, June 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that U.K.-based Rothamsted Research Limited ("Rothamsted") has granted to the Company an exclusive global, commercial license to advanced technology for producing sustainable omega-3 products in Camelina sativa ("Camelina"). Yield10 is executing a plan to use engineered Camelina to commercially produce omega-3 oil and meal products targeting the aquafeed, petfood, and nutritional markets for omega-3 fatty acids. In consideration for the commercial license, Yield10 is expected to pay certain license fees, future milestone payments, and royalties based on commercialization of Rothamsted's omega-3 technology.

    Producing omega-3 fatty acids in engineered Camelina may represent a way to enable a predictable, land-based supply of high-quality omega-3 oils to meet the growing global demand for eicosapentaenoic acid ("EPA") and docosahexaenoic acid ("DHA"). Currently, the primary source of EPA and DHA is ocean-caught fish, where omega-3 oil produced from anchovy harvest is the industry benchmark. Over the last few years, there has been increasing pressure on the supply of omega-3 oil due to over-fishing. The potential market opportunity for omega-3 fatty acids produced in Camelina includes use in pharmaceutical (ethyl-EPA) products, dietary supplements, and food and feed ingredients.

    "Over the last three years, the Yield10 team has provided us with expertise and support as our team has advanced the development of engineered Camelina from field testing to planting at multi-acre scale to produce omega-3 oil," said Professor Angela Karp, Rothamsted director and chief executive officer. "Yield10's innovations and capabilities in Camelina are impressive and successful commercialization of this technology could have significant benefits, offering sustainable production of an oil essential for nutrition and wellness to consumers, as well as providing crop diversification to growers. We look forward to the commercialization of omega-3 oil and meal products by Yield10 in the years ahead."

    "Enabled by the Rothamsted technology, we are on a promising path to commercializing elite omega-3 producing varieties of Camelina that combine good agronomics in the field while also producing high-value, high-purity omega-3 oils possessing very attractive economics," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. "In 2024, we are positioned to execute on the scale-up of omega-3 producing Camelina and to submit key regulatory filings with the goal of being ready for an initial commercial launch into the oil and meal markets. We also look forward to improving the current Camelina varieties over time particularly with the deployment of herbicide tolerance and other performance traits."

    In late 2020, Yield10 began a collaboration with Rothamsted to support Rothamsted's Flagship Program to develop omega-3 oils in Camelina. The advanced technology developed by Rothamsted enables the sustainable, plant-based production of omega-3 nutritional oils in Camelina. Over the last decade, the Rothamsted team, led by Professor Johnathan Napier, Ph.D., Science Director, has demonstrated the production of omega-3 oils in Camelina seed and conducted evaluations of the oils in salmon feeding and human clinical studies to demonstrate lipid lowering effects.

    Recent Achievements in Yield10's Omega-3 Camelina Program

    • In the spring of 2024, Yield10 planted omega-3 (EPA and EPA+DHA) Camelina to scale up seed. Yield10 is also field testing for the first time herbicide tolerant omega-3 Camelina lines to guide selection of commercial quality lead and back-up lines.
    • In the fall of 2023, Yield10 planted omega-3 (EPA) Camelina at the 50 acre-scale in Chile to produce oil for use in business development activities. The crop was harvested in early 2024.
    • In March of 2024, USDA-APHIS provided a positive response to the Company's announced filings for two requests for a Regulatory Status Review ("RSR") with USDA-APHIS's Biotechnology Regulatory Services (BRS) under the SECURE Rule for proprietary elite Camelina varieties containing genes enabling the plant to produce the EPA and EPA+DHA components of omega-3 oil. Yield10 plans to conduct seed scale-up activities with omega-3 Camelina in 2024. Omega-3 fatty acids are used in aquafeed as well as for nutraceutical and pharmaceutical products.
    • In November of 2023, USDA-APHIS determined that Yield10's glufosinate tolerant Camelina as well as its stacked herbicide tolerant Camelina may be planted and bred in the United States in response to two RSR packages submitted by Yield10.

    • In October 2023, Yield10 announced it had signed a non-binding Letter of Intent ("LOI") with BioMar Group, a global aquafeed producer, to form a partnership to commercialize Camelina engineered to produce omega-3 oil for use as a high-quality supplement to the scarce supply of marine long-chain fatty acids used in aquafeed. The companies are working to develop a collaborative program to bring this new source of high-quality EPA and EPA+DHA omega-3 oils to the market.

    About Rothamsted Research

    Rothamsted Research is the longest-running agricultural research institute in the world. We work from gene to field with a proud history of ground-breaking discoveries, from crop treatment to crop protection, from statistical interpretation to soils management. In 1843, our founders were the pioneers of modern agriculture, and we are known for our imaginative science and our collaborative influence on fresh thinking and farming practices. Through independent science and innovation, Rothamsted has made significant contributions to improving agri-food systems in the UK and internationally. In terms of the institute's economic contribution, the cumulative impact of our work in the UK was calculated to exceed £3000 million a year in 20151. Rothamsted Research is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), with additional support from other national and international funding streams, and from industry. It is also supported by the Lawes Agricultural Trust (LAT).

    For more information, visit the Rothamsted website or follow on X (formerly Twitter) @Rothamsted

    About Yield10 Bioscience

    Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa ("Camelina") as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics. Subject to the availability of sufficient financial resources to continue operations, our commercial plan is based on establishing a grain contracting business leveraging our proprietary elite Camelina seed varieties, focusing on the growing demand for low-carbon intensity feedstock oil for biofuels and omega-3 oils for nutritional applications. Yield10 is headquartered in Woburn, MA and has a Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon, Canada.

    For more information about the Company, please visit www.yield10bio.com, or follow the Company on X (formerly Twitter), Facebook and LinkedIn.

    (YTEN-G)

    Safe Harbor for Forward-Looking Statements

    This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, the development of EPA and EPA+DHA Camelina and the performance and production capacity of the omega-3 production technology, the potential for large-scale production of EPA8 Camelina, the future commercialization, potential market opportunity, economic viability and further development of the omega-3 varieties of Camelina and the omega-3 oils produced therefrom, and the potential for the omega-3 production technology to provide sustainable alternatives to existing means of omega-3 oil production, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the Company's ability to secure adequate funding in the near term to continue operations, as to which no assurance can be given, as well as the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.

    Contacts:

    Rothamsted Research:

    James Clarke, Head of Communications

    +44 7964 832719, [email protected]

    Yield10 Bioscience:

    Lynne H. Brum, (617) 682-4693, [email protected]



    Primary Logo

    Get the next $YTEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YTEN

    DatePrice TargetRatingAnalyst
    2/8/2024Buy → Hold
    Lake Street
    3/10/2022$18.00 → $9.00Buy
    Maxim Group
    More analyst ratings

    $YTEN
    SEC Filings

    See more
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      12/6/24 4:57:07 PM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      11/22/24 10:39:21 AM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      11/12/24 11:49:02 AM ET
      $YTEN

    $YTEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Schuler Jack W bought $497,250 worth of shares (765,000 units at $0.65) (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      10/10/23 4:41:49 PM ET
      $YTEN

    $YTEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Yield10 Bioscience Inc. (Amendment)

      SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      5/23/24 5:51:39 PM ET
      $YTEN
    • SEC Form SC 13D filed by Yield10 Bioscience Inc.

      SC 13D - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      10/11/23 4:05:24 PM ET
      $YTEN
    • SEC Form SC 13D/A filed by Yield10 Bioscience Inc. (Amendment)

      SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      5/26/23 1:14:08 PM ET
      $YTEN

    $YTEN
    Financials

    Live finance-specific insights

    See more
    • Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

      -Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023. "In 2023 we successfully executed our plan and achieved several

      4/1/24 4:01:07 PM ET
      $YTEN
    • Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

      WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024. Management will host a conference call on Monday, April 1, 2024.at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-877-709-8150 or +1-201-689-8354 (international) to listen to the call. Th

      3/28/24 4:01:20 PM ET
      $YTEN
    • Yield10 Bioscience to Announce Third Quarter 2023 Financial Results and Host a Conference Call on Tuesday, November 14, 2023

      WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023. Management will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-800-715-9871 or +1-646-307-1963 (international) to listen to the call. The Conf

      11/8/23 8:31:35 AM ET
      $YTEN

    $YTEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals

      Special Meeting Adjourned to Thursday, November 21, 2024 WOBURN, MA / ACCESSWIRE / November 8, 2024 / Yield10 Bioscience, Inc. (OTCQB:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that its Special Meeting of Stockholders (the "Special Meeting"), scheduled to be held at 11:00 a.m., Eastern Time, on November 8, 2024, was convened and adjourned, without any business being conducted, due to lack of sufficient votes in favor of the key proposals related to the Asset Sale to Nuseed and the Dissolution proposal.To pass the proposals, more than 50% of the shares of common stock outstanding and entitled to vote as of the close of business on October 3, 2024

      11/8/24 11:20:00 AM ET
      $YTEN
    • Yield10 Bioscience Announces Second Quarter 2024 Financial Results

      WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. "We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our shareholders, business partners, and employees. Receipt of the initial $3 million payment and progress toward earning an additional $2 million milestone payment is enabling

      8/14/24 4:37:26 PM ET
      $YTEN
    • Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

      WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina. Nufarm and Yield10 have additionally agreed to immediately negotiate exclusively with each other for the sale of Yield10's remaining assets to Nufarm. The asset sale will require an affirmative vote

      7/17/24 6:45:00 PM ET
      $YTEN

    $YTEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP Research and CSO Snell Kristi covered exercise/tax liability with 877 shares, decreasing direct ownership by 11% to 6,999 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/20/24 3:15:23 PM ET
      $YTEN
    • VP Planning and Communications Brum Lynne H covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,867 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/19/24 8:11:23 PM ET
      $YTEN
    • VP Finance and CAO Haaser Charles B covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,949 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/19/24 8:10:36 PM ET
      $YTEN

    $YTEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Yield10 Bioscience downgraded by Lake Street

      Lake Street downgraded Yield10 Bioscience from Buy to Hold

      2/8/24 7:25:58 AM ET
      $YTEN
    • Maxim Group reiterated coverage on Yield10 Bioscience with a new price target

      Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $9.00 from $18.00 previously

      3/10/22 9:38:04 AM ET
      $YTEN
    • Maxim Group reiterated coverage on Yield10 Bioscience with a new price target

      Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $24.00 from $12.00 previously

      2/9/21 4:14:42 PM ET
      $YTEN

    $YTEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Yield10 Bioscience Appoints Willie Loh, Ph.D., Former Cargill Executive, to the Board of Directors

      WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Willie Loh, Ph.D., was named to the Company's Board of Directors effective October 4, 2022. Dr. Loh previously served as a Special Commercial and Technical Advisor to the Company. Dr. Loh was formerly Vice President, Market Development of Cargill Inc.'s Global Edible Oils Solutions group in North America. Cargill is a global food and agriculture company. "We are delighted that Willie is expanding his role with Yield10 by serving on our Board of Directors," said Oliver Peoples, Ph.D., Chief Executive Officer of Yield1

      10/5/22 8:30:20 AM ET
      $YTEN